<p>Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - 獲取免費報告) 董事 Hongbo Lu 於 5 月 12 日星期二出售了 2,970 股公司股票。股票以平均價格 $76.88 出售，總價值為 $228,333.60。交易後，該董事持有 52,012 股公司股票，估值約為 $3,998,682.56。這代表其持股減少了 5.40%。此次出售在向證券交易委員會的備案中披露，相關信息可通過 SEC 網站訪問。該交易是在預先安排的 10b5-1 交易計劃下執行的。</p>
<h2>Arrowhead Pharmaceuticals 股價上漲 2.3%</h2>
<ul>
<li>想要在生物技術領域獲得多元化的上行潛力？查看 LABU</li>
</ul>
<p>ARWR 的股票在週四的交易時段上漲了 $1.81，達到 $79.69。該公司交易了 1,799,277 股，較其平均交易量 1,916,164 股有所減少。公司的 50 日移動平均價格為 $65.71，200 日移動平均價格為 $61.75。公司的速動比率為 6.23，流動比率為 6.23，債務與股本比率為 1.41。公司的市值為 112.3 億美元，市盈率為 -37.06，貝塔值為 1.28。Arrowhead Pharmaceuticals, Inc. 的 12 個月低點為 $14.30，12 個月高點為 $82.26。</p>
<p>Arrowhead Pharmaceuticals (NASDAQ:ARWR - 獲取免費報告) 最近於 5 月 7 日星期四發佈了季度財報。該生物技術公司報告本季度每股收益為 ($0.93)，超出市場共識預期的 ($1.10) $0.17。該公司本季度的收入為 $73.74 百萬美元，而分析師預期為 $73.84 百萬美元。Arrowhead Pharmaceuticals 的股本回報率為 -55.09%，淨利潤率為 -48.38%。該公司的收入同比下降了 86.4%。在去年同期，該公司每股收益為 $2.75。股票研究分析師預測 Arrowhead Pharmaceuticals, Inc. 本財年每股收益將為 -2.97。</p>
<h2>機構投資者對 Arrowhead Pharmaceuticals 的看法</h2>
<p>幾家對沖基金和其他機構投資者最近對 ARWR 的持倉進行了調整。Siren L.L.C. 在第一季度將其在 Arrowhead Pharmaceuticals 的股份增加了 7.7%。Siren L.L.C. 目前持有 1,615,476 股該生物技術公司的股票，價值 $101,290,000，此前在上個季度購買了額外的 115,000 股。Inceptionr LLC 在第一季度購買了 Arrowhead Pharmaceuticals 的新股份，價值 $426,000。諾瓦斯科舍銀行在第一季度購買了 Arrowhead Pharmaceuticals 的新股份，價值 $8,525,000。Cetera Investment Advisers 在第一季度將其在 Arrowhead Pharmaceuticals 的股份增加了 40.7%。Cetera Investment Advisers 目前持有 9,424 股該生物技術公司的股票，價值 $591,000，此前在上個季度購買了額外的 2,727 股。最後，WCM Investment Management LLC 在第一季度將其在 Arrowhead Pharmaceuticals 的持股增加了 23.5%。WCM Investment Management LLC 目前持有 171,575 股該生物技術公司的股票，估值為 $9,891,000，此前在此期間獲得了額外的 32,670 股。對沖基金和其他機構投資者持有該公司 62.61% 的股份。</p>
<h2>分析師設定新的價格目標</h2>
<p>多家券商最近對 ARWR 發表了評論。Sanford C. Bernstein 將 Arrowhead Pharmaceuticals 的價格目標從 $35.00 上調至 $46.00，並在週三的研究報告中給予該股票 “市場表現” 評級。HC Wainwright 在 3 月 25 日的報告中重申了 “買入” 評級，並設定了 $100.00 的價格目標。B. Riley Financial 在 1 月 22 日的研究報告中將 Arrowhead Pharmaceuticals 的價格目標從 $61.00 上調至 $101.00，並給予該股票 “買入” 評級。摩根大通在 5 月 1 日的研究報告中開始覆蓋 Arrowhead Pharmaceuticals 的股票。他們設定了 “增持” 評級和 $88.00 的價格目標。最後，加拿大皇家銀行在 5 月 8 日的研究報告中將 Arrowhead Pharmaceuticals 的價格目標從 $80.00 上調至 $87.00，並給予該公司 “跑贏大盤” 評級。一位分析師給予該股票 “強烈買入” 評級，八位給予 “買入” 評級，三位給予 “持有” 評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “適度買入”，平均目標價格為 $87.80。</p>
<p><strong>查看我們對 ARWR 的最新分析</strong></p>
<h2>更多 Arrowhead Pharmaceuticals 新聞</h2>
<p>以下是本週影響 Arrowhead Pharmaceuticals 的主要新聞故事：</p>
<ul>
<li>積極情緒：HC Wainwright 對 Arrowhead Pharmaceuticals 維持 <strong>買入</strong> 評級，並保持 <strong>$100 的目標價</strong>，同時上調了一些中長期的盈利預測，包括 FY2026 和 2026 年第四季度的預估。Arrowhead Pharmaceuticals 分析師估計更新</li>
<li>積極情緒：Sanford C. Bernstein 將其 <strong>目標價從 $35 上調至 $46</strong>，表明對 Arrowhead 前景的信心有所增強，儘管其評級仍為 <strong>市場表現</strong>。Bernstein 上調 Arrowhead 目標價</li>
<li>中性情緒：HC Wainwright 對幾個季度的每股收益預估僅進行了小幅修訂，有些季度略低，有些季度略高，表明 Arrowhead 的管線驅動盈利路徑整體論點沒有重大變化。HC Wainwright 估計修訂</li>
<li>中性情緒：最近的報道還強調了 Arrowhead 正在進行的估值辯論和即將公佈的臨牀結果，這可能在關鍵催化劑之前保持了投資者的興趣。2026 年下半年多個重要臨牀結果</li>
<li>消極情緒：HC Wainwright 下調了 Arrowhead 的幾個短期盈利預測，包括 2026 年第三季度、2027 年第一季度和 2027 年第二季度，這反映了對持續虧損的預期，直到最終改善。Arrowhead 短期盈利估計下調</li>
</ul>
<h2>關於 Arrowhead Pharmaceuticals</h2>
<p>(獲取免費報告)</p>
<p>Arrowhead Pharmaceuticals, Inc 是一家臨牀階段的生物製藥公司，專注於 RNA 干擾 (RNAi) 治療藥物的發現、開發和商業化。自 2008 年成立以來，Arrowhead 利用其專有的遞送平台——內部稱為先進 RNAi 化合物 (ARC) 技術——來沉默患有遺傳性疾病的患者體內致病基因。該公司的方法旨在提供持久的、針對性的治療，涵蓋多個治療領域。</p>
<p>該公司的管線包括多個處於不同開發階段的候選藥物。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Arrowhead Pharmaceuticals</li>
<li>YETI 在盈利超預期和上調前景後反彈</li>
<li>三家領先的量子公司在第一季度盈利後的對比</li>
<li>思科的垂直反彈可能仍處於早期階段</li>
<li>亞馬遜與阿里巴巴：現在顯然更具價值的選擇</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 $1,000 在 Arrowhead Pharmaceuticals 嗎？</h2>
<p>在考慮 Arrowhead Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛市場注意到之前立即購買的股票……而 Arrowhead Pharmaceuticals 並不在名單上。</p>
<p>雖然 Arrowhead Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

箭頭制藥

標普全球醫療股指數 ETF - iShares

2 倍做多納斯達克生物技術 ETF - ProShares

<p>箭頭製藥董事盧洪波以每股 76.88 美元的價格出售了 2,970 股，總計 228,333.60 美元，減少了 5.40% 的持股比例。出售後，他持有 52,012 股，估值約為 399 萬美元。該交易已向美國證券交易委員會（SEC）披露，並在 10b5-1 規則下執行。該股票最近上漲了 2.3%，交易價格為 79.69 美元，市值為 112.3 億美元，上一季度每股收益為-0.93 美元</p>

<p>Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) Director Hongbo Lu sold 2,970 shares of the company's stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $76.88, for a total value of $228,333.60. Following the transaction, the director owned 52,012 shares of the company's stock, valued at approximately $3,998,682.56. This represents a 5.40% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.</p>
<div class="lb-trans"><p>Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - 獲取免費報告) 董事 Hongbo Lu 於 5 月 12 日星期二出售了 2,970 股公司股票。股票以平均價格 $76.88 出售，總價值為 $228,333.60。交易後，該董事持有 52,012 股公司股票，估值約為 $3,998,682.56。這代表其持股減少了 5.40%。此次出售在向證券交易委員會的備案中披露，相關信息可通過 SEC 網站訪問。該交易是在預先安排的 10b5-1 交易計劃下執行的。</p>
</div><h2>Arrowhead Pharmaceuticals Trading Up 2.3%</h2>
<div class="lb-trans"><h2>Arrowhead Pharmaceuticals 股價上漲 2.3%</h2>
</div><ul>
<li>Want Diversified Upside in Biotechnology? Check out LABU</li>
</ul>
<div class="lb-trans"><ul>
<li>想要在生物技術領域獲得多元化的上行潛力？查看 LABU</li>
</ul>
</div><p>Shares of ARWR traded up $1.81 during trading hours on Thursday, reaching $79.69. 1,799,277 shares of the company traded hands, compared to its average volume of 1,916,164. The company's fifty day moving average price is $65.71 and its two-hundred day moving average price is $61.75. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 1.41. The company has a market capitalization of $11.23 billion, a price-to-earnings ratio of -37.06 and a beta of 1.28. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $14.30 and a 12 month high of $82.26.</p>
<div class="lb-trans"><p>ARWR 的股票在週四的交易時段上漲了 $1.81，達到 $79.69。該公司交易了 1,799,277 股，較其平均交易量 1,916,164 股有所減少。公司的 50 日移動平均價格為 $65.71，200 日移動平均價格為 $61.75。公司的速動比率為 6.23，流動比率為 6.23，債務與股本比率為 1.41。公司的市值為 112.3 億美元，市盈率為 -37.06，貝塔值為 1.28。Arrowhead Pharmaceuticals, Inc. 的 12 個月低點為 $14.30，12 個月高點為 $82.26。</p>
</div><p>Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, beating the consensus estimate of ($1.10) by $0.17. The company had revenue of $73.74 million for the quarter, compared to analyst estimates of $73.84 million. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.The firm's revenue was down 86.4% on a year-over-year basis. During the same period in the previous year, the company posted $2.75 earnings per share. Equities research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.97 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Arrowhead Pharmaceuticals (NASDAQ:ARWR - 獲取免費報告) 最近於 5 月 7 日星期四發佈了季度財報。該生物技術公司報告本季度每股收益為 ($0.93)，超出市場共識預期的 ($1.10) $0.17。該公司本季度的收入為 $73.74 百萬美元，而分析師預期為 $73.84 百萬美元。Arrowhead Pharmaceuticals 的股本回報率為 -55.09%，淨利潤率為 -48.38%。該公司的收入同比下降了 86.4%。在去年同期，該公司每股收益為 $2.75。股票研究分析師預測 Arrowhead Pharmaceuticals, Inc. 本財年每股收益將為 -2.97。</p>
</div><h2>Institutional Investors Weigh In On Arrowhead Pharmaceuticals</h2>
<div class="lb-trans"><h2>機構投資者對 Arrowhead Pharmaceuticals 的看法</h2>
</div><p>Several hedge funds and other institutional investors have recently made changes to their positions in ARWR. Siren L.L.C. increased its stake in shares of Arrowhead Pharmaceuticals by 7.7% in the first quarter. Siren L.L.C. now owns 1,615,476 shares of the biotechnology company's stock worth $101,290,000 after purchasing an additional 115,000 shares in the last quarter. Inceptionr LLC bought a new position in Arrowhead Pharmaceuticals in the 1st quarter worth $426,000. Bank of Nova Scotia purchased a new stake in Arrowhead Pharmaceuticals in the 1st quarter worth $8,525,000. Cetera Investment Advisers increased its stake in Arrowhead Pharmaceuticals by 40.7% in the 1st quarter. Cetera Investment Advisers now owns 9,424 shares of the biotechnology company's stock worth $591,000 after buying an additional 2,727 shares in the last quarter. Finally, WCM Investment Management LLC raised its holdings in Arrowhead Pharmaceuticals by 23.5% during the first quarter. WCM Investment Management LLC now owns 171,575 shares of the biotechnology company's stock valued at $9,891,000 after acquiring an additional 32,670 shares during the period. Hedge funds and other institutional investors own 62.61% of the company's stock.</p>
<div class="lb-trans"><p>幾家對沖基金和其他機構投資者最近對 ARWR 的持倉進行了調整。Siren L.L.C. 在第一季度將其在 Arrowhead Pharmaceuticals 的股份增加了 7.7%。Siren L.L.C. 目前持有 1,615,476 股該生物技術公司的股票，價值 $101,290,000，此前在上個季度購買了額外的 115,000 股。Inceptionr LLC 在第一季度購買了 Arrowhead Pharmaceuticals 的新股份，價值 $426,000。諾瓦斯科舍銀行在第一季度購買了 Arrowhead Pharmaceuticals 的新股份，價值 $8,525,000。Cetera Investment Advisers 在第一季度將其在 Arrowhead Pharmaceuticals 的股份增加了 40.7%。Cetera Investment Advisers 目前持有 9,424 股該生物技術公司的股票，價值 $591,000，此前在上個季度購買了額外的 2,727 股。最後，WCM Investment Management LLC 在第一季度將其在 Arrowhead Pharmaceuticals 的持股增加了 23.5%。WCM Investment Management LLC 目前持有 171,575 股該生物技術公司的股票，估值為 $9,891,000，此前在此期間獲得了額外的 32,670 股。對沖基金和其他機構投資者持有該公司 62.61% 的股份。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的價格目標</h2>
</div><p>A number of brokerages have recently commented on ARWR. Sanford C. Bernstein boosted their price target on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a &#34;market perform&#34; rating in a research report on Wednesday. HC Wainwright restated a &#34;buy&#34; rating and set a $100.00 price target on shares of Arrowhead Pharmaceuticals in a report on Wednesday, March 25th. B. Riley Financial upped their price target on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, January 22nd. JPMorgan Chase &amp; Co. initiated coverage on shares of Arrowhead Pharmaceuticals in a research report on Friday, May 1st. They set an &#34;overweight&#34; rating and a $88.00 price objective on the stock. Finally, Royal Bank Of Canada raised their price objective on shares of Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the company an &#34;outperform&#34; rating in a research note on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $87.80.</p>
<div class="lb-trans"><p>多家券商最近對 ARWR 發表了評論。Sanford C. Bernstein 將 Arrowhead Pharmaceuticals 的價格目標從 $35.00 上調至 $46.00，並在週三的研究報告中給予該股票 “市場表現” 評級。HC Wainwright 在 3 月 25 日的報告中重申了 “買入” 評級，並設定了 $100.00 的價格目標。B. Riley Financial 在 1 月 22 日的研究報告中將 Arrowhead Pharmaceuticals 的價格目標從 $61.00 上調至 $101.00，並給予該股票 “買入” 評級。摩根大通在 5 月 1 日的研究報告中開始覆蓋 Arrowhead Pharmaceuticals 的股票。他們設定了 “增持” 評級和 $88.00 的價格目標。最後，加拿大皇家銀行在 5 月 8 日的研究報告中將 Arrowhead Pharmaceuticals 的價格目標從 $80.00 上調至 $87.00，並給予該公司 “跑贏大盤” 評級。一位分析師給予該股票 “強烈買入” 評級，八位給予 “買入” 評級，三位給予 “持有” 評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “適度買入”，平均目標價格為 $87.80。</p>
</div><p><strong>View Our Latest Analysis on ARWR</strong></p>
<div class="lb-trans"><p><strong>查看我們對 ARWR 的最新分析</strong></p>
</div><h2>More Arrowhead Pharmaceuticals News</h2>
<div class="lb-trans"><h2>更多 Arrowhead Pharmaceuticals 新聞</h2>
</div><p>Here are the key news stories impacting Arrowhead Pharmaceuticals this week:</p>
<div class="lb-trans"><p>以下是本週影響 Arrowhead Pharmaceuticals 的主要新聞故事：</p>
</div><ul>
<li>Positive Sentiment: HC Wainwright kept a <strong>Buy</strong> rating on Arrowhead Pharmaceuticals and maintained a <strong>$100 price target</strong>, while also raising some medium- and longer-term earnings forecasts, including FY2026 and Q4 2026 estimates. Arrowhead Pharmaceuticals analyst estimate updates</li>
<li>Positive Sentiment: Sanford C. Bernstein raised its <strong>price target from $35 to $46</strong>, signaling improved confidence in Arrowhead’s outlook, even though its rating remains <strong>Market Perform</strong>. Bernstein raises Arrowhead price target</li>
<li>Neutral Sentiment: HC Wainwright made only small revisions to several quarterly EPS estimates, with some quarters slightly lower and others slightly higher, suggesting no major change in the overall thesis for Arrowhead’s pipeline-driven earnings path. HC Wainwright estimate revisions</li>
<li>Neutral Sentiment: Recent coverage also highlighted Arrowhead’s ongoing valuation debate and upcoming clinical readouts, which may be keeping investor interest elevated ahead of key catalysts. Multiple important clinical readouts in 2H26</li>
<li>Negative Sentiment: HC Wainwright trimmed several near-term earnings forecasts for Arrowhead, including Q3 2026, Q1 2027 and Q2 2027, which reflects expectations for continued losses before eventual improvement. Arrowhead near-term earnings estimate cuts</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：HC Wainwright 對 Arrowhead Pharmaceuticals 維持 <strong>買入</strong> 評級，並保持 <strong>$100 的目標價</strong>，同時上調了一些中長期的盈利預測，包括 FY2026 和 2026 年第四季度的預估。Arrowhead Pharmaceuticals 分析師估計更新</li>
<li>積極情緒：Sanford C. Bernstein 將其 <strong>目標價從 $35 上調至 $46</strong>，表明對 Arrowhead 前景的信心有所增強，儘管其評級仍為 <strong>市場表現</strong>。Bernstein 上調 Arrowhead 目標價</li>
<li>中性情緒：HC Wainwright 對幾個季度的每股收益預估僅進行了小幅修訂，有些季度略低，有些季度略高，表明 Arrowhead 的管線驅動盈利路徑整體論點沒有重大變化。HC Wainwright 估計修訂</li>
<li>中性情緒：最近的報道還強調了 Arrowhead 正在進行的估值辯論和即將公佈的臨牀結果，這可能在關鍵催化劑之前保持了投資者的興趣。2026 年下半年多個重要臨牀結果</li>
<li>消極情緒：HC Wainwright 下調了 Arrowhead 的幾個短期盈利預測，包括 2026 年第三季度、2027 年第一季度和 2027 年第二季度，這反映了對持續虧損的預期，直到最終改善。Arrowhead 短期盈利估計下調</li>
</ul>
</div><h2>About Arrowhead Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Arrowhead Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.</p>
<div class="lb-trans"><p>Arrowhead Pharmaceuticals, Inc 是一家臨牀階段的生物製藥公司，專注於 RNA 干擾 (RNAi) 治療藥物的發現、開發和商業化。自 2008 年成立以來，Arrowhead 利用其專有的遞送平台——內部稱為先進 RNAi 化合物 (ARC) 技術——來沉默患有遺傳性疾病的患者體內致病基因。該公司的方法旨在提供持久的、針對性的治療，涵蓋多個治療領域。</p>
</div><p>The company's pipeline includes multiple candidates in various stages of development.</p>
<div class="lb-trans"><p>該公司的管線包括多個處於不同開發階段的候選藥物。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Arrowhead Pharmaceuticals</li>
<li>YETI Rallies After Earnings Beat and Raised Outlook</li>
<li>How the 3 Leading Quantum Firms Stack Up After Q1 Earnings</li>
<li>Cisco’s Vertical Rally May Still Be in the Early Innings</li>
<li>Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Arrowhead Pharmaceuticals</li>
<li>YETI 在盈利超預期和上調前景後反彈</li>
<li>三家領先的量子公司在第一季度盈利後的對比</li>
<li>思科的垂直反彈可能仍處於早期階段</li>
<li>亞馬遜與阿里巴巴：現在顯然更具價值的選擇</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=ARWR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Arrowhead Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Arrowhead Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Arrowhead Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛市場注意到之前立即購買的股票……而 Arrowhead Pharmaceuticals 並不在名單上。</p>
</div><p>While Arrowhead Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Arrowhead Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Sells 2,970 Shares of Stock

Market Beat

紐交所高增長板生物技術指數 ETF - First Trust

醫藥突破 ETF - ALPS

動態生物技術與基因組 ETF - Invesco

標普生物技術 ETF - SPDR

醫療業 ETF - SPDR

標普生物技術 3 倍做多 - Direxion

美國制藥 ETF - iShares

基因改革 ETF - ARK

生物科技 ETF - VanEck Vectors

納斯達克生物科技指數 ETF - iShares Nasdaq

標普生物技術 3 倍做空 - Direxion

醫療業 ETF - Vanguard

Bank of Nova Scottia

摩根大通

加拿大皇家銀行

B Riley Financial Pref Share RILYL 7.375 Perp 09/04/25 B

B Riley Financial Pref Share RILYG 7.25 12/21/27

B Riley Financial Pref Share RILYN 6.5 09/30/2026

B Riley Financial Pref Share RILYK 5.5 03/31/26

B. Riley Financial-存託優先股A

B Riley Financial Pref Share RILYZ 5.25 08/31/28

B Riley Financial Pref Share RILYT 6.0 01/31/28

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

內幕交易：ArrowHead Pharma（NASDAQ:ARWR）的董事出售了 2,970 股股票